К основному контенту

Is Viagra Bad For You?

Short answer

If you do not have erectile dysfunction, yes it is bad for you! If you do have ED be sure to take under the consent of your doctor.


Long answer

Viagra is used mostly by men ages 50-60 specifically for erectile dysfunction, or in other words where the heart cannot pump enough blood to become erect. However, recreational use of viagra by younger men has become increasingly popular in the last few years. If you do not have ED (erectile dysfunction) you SHOULD NOT use viagra. It is not a libido booster, and will most likely lead to unwanted side effects if you are not using it properly.

To start off, using viagra recreationally will most likely result in becoming dependent on it, resulting in actually developing erectile dysfunction. This means it will become "hard to get hard", and you will find yourself needing viagra to have sex (possibly even more powerful remedies in the future - such as injections or implants). Taking viagra on a normal basis can lead to side effects such as nosebleeds, muscle pain, diarrhea, headaches, sleeping trouble, bladder / urination pain, and dizziness. You may also find yourself with an erection lasting longer than 4 hours (most common side effect), which can be extremely painful. If this happens to you, you should consult a physician immediately.

If you are using viagra for its true purpose and are taking it under the approval / watch of your doctor, you most likely won't experience any problems. However, it's good to note that viagra shouldn't be mixed with other medicines that contain nitrates. Many symptoms can arise from this such as blurred vision, liver problems, and heart attacks (although rare).

 Brand Viagra by PFIZER Company

Комментарии

Популярные сообщения из этого блога

A healthy diet may trigger a better response to a certain kind of melanoma treatment. How?

New research suggests that a diet that's full of fiber appears to lead to more diverse intestinal bacteria (microbiome). In turn, a thriving gut microbiome is linked to a stronger response to an immune therapy for the aggressive skin cancer. "We found that patients eating a high-fiber diet at the start of therapy were about five times more likely to respond to the anti-PD-1 immunotherapy," said study author Christine Spencer. She's a research scientist with the Parker Institute for Cancer Immunotherapy in San Francisco. Anti-PD-1 immunotherapy helps the immune system recognize cancer cells as dangerous cells that need to be destroyed, according to the American Cancer Society (ACS). The cancer drugs Keytruda and Opdivo are examples of this type of immunotherapy. Melanoma is a type of skin cancer. It only accounts for about 1 percent of all skin cancers, but is responsible for most skin cancer deaths, the ACS says. Several recent studies have suggested that a ...

American Heart Association News

On Feb. 1, 1961, twins Debbie and Donna Horst arrived at the White House to fanfare. The 6-year-olds, decked out in fancy dresses and satin sashes, found themselves surrounded by a pressing crowd and a sea of blinding flashbulbs as they made their way to see Jacqueline Kennedy. The girls -- both born with holes in their aortas -- were meeting with the first lady to kick off a national campaign to raise awareness about congenital heart defects. "There were hundreds of reporters because this was Jacqueline Kennedy' first public act as first lady," Debbie said. She recalls being startled when the reporters asked Mrs. Kennedy if they could move in closer. "It was frightening because they all jumped at us at once." The Pennsylvania twins, just a few weeks from turning 7, were among the first "Heart Fund Sweethearts" in the campaign to raise money as well as awareness. The month before, they'd met up with Micki and Patricia Gane, also of Pennsylvania...

Agile Therapeutics Resubmits New Drug Application (NDA) for its Transdermal Low-Dose

Agile Therapeutics Resubmits New Drug Application (NDA) for its Transdermal Low-Dose Contraceptive Patch, Twirla PRINCETON, N.J., May 17, 2019 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today announced it has resubmitted to the U.S. Food and Drug Administration (FDA) the NDA for its lead product candidate, Twirla®, an investigational low-dose combined hormonal contraceptive patch (AG200-15).  Agile resubmitted the NDA in response to a December 2017 Complete Response Letter (CRL) from the FDA, which identified deficiencies relating to (i) quality control adhesion test methods for the Twirla manufacturing process, (ii) observations identified during an inspection of a facility of our third-party manufacturer for the Twirla NDA that must be resolved, and (iii) questions on the in vivo adhesion properties of Twirla and their potential relationship to the SECURE clinical trial results. The resubmitted NDA includes the results from a...